DK1886559T3 - Blodpladeadditivopløsning - Google Patents
Blodpladeadditivopløsning Download PDFInfo
- Publication number
- DK1886559T3 DK1886559T3 DK07253015.7T DK07253015T DK1886559T3 DK 1886559 T3 DK1886559 T3 DK 1886559T3 DK 07253015 T DK07253015 T DK 07253015T DK 1886559 T3 DK1886559 T3 DK 1886559T3
- Authority
- DK
- Denmark
- Prior art keywords
- platelet
- platelet additive
- additive solution
- pas
- viscosity
- Prior art date
Links
- 239000000654 additive Substances 0.000 title claims description 70
- 230000000996 additive effect Effects 0.000 title claims description 70
- 239000000243 solution Substances 0.000 claims description 91
- 239000003795 chemical substances by application Substances 0.000 claims description 60
- 229920002123 Pentastarch Polymers 0.000 claims description 47
- 229940101738 pentastarch Drugs 0.000 claims description 47
- 229920002557 polyglycidol polymer Polymers 0.000 claims description 26
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 239000003634 thrombocyte concentrate Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 238000003032 molecular docking Methods 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 229940050410 gluconate Drugs 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 239000002195 soluble material Substances 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 16
- 238000004090 dissolution Methods 0.000 claims 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- 238000011176 pooling Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 description 111
- 210000002381 plasma Anatomy 0.000 description 47
- 238000004519 manufacturing process Methods 0.000 description 22
- 239000000306 component Substances 0.000 description 18
- 238000011084 recovery Methods 0.000 description 15
- 239000012503 blood component Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 241000238413 Octopus Species 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 229940125691 blood product Drugs 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000010118 platelet activation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
- -1 Hydroxyethyl groups Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000223 polyglycerol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
Claims (18)
1. Blodpladeadditivopløsning (platelet additive solution - PAS) omfattende et viskositetsforøgende middel tilvejebragt ved en koncentration, der er effektiv til opnåelse af en PAS-viskositet i området fra 1,128 centipoise til 1,228 centipoise når målt ved 37 °C, hvor det viskositetsforøgende middel er hydroxyethylstivelse (valgfrit pentastivelse) eller polyglycidol.
2. Blodpladeadditivopløsning ifølge krav 1, hvor hydroxyethylstivelsen omfatter pentastivelse.
3. Blodpladeadditivopløsning ifølge krav 1, hvor det viskositetsforøgende middel tilvejebringes ved en koncentration, der er effektiv til opnåelse af en PAS-viskositet på omkring 1,178 centipoise.
4. Blodpladeadditivopløsning ifølge et hvilket som helst af kravene 1 til 3, yderligere omfattende mindst én energikilde, mindst én bufferkomponent, mindst ét chelateringsmiddel, mindst én saltkomponent og valgfrit mindst én metabolisk regulator og/eller membranpolaritetsstabiliserende komponent.
5. Blodpladeadditivopløsning ifølge krav 4, hvor den mindst ene saltkomponent tilvejebringes ved en koncentration, der er tilstrækkelig til at give en PAS-osmolalitet i området fra 250 mOsm til 400 mOsm.
6. Blodpladeadditivopløsning ifølge krav 5, hvor den mindst ene saltkomponent tilvejebringes ved en koncentration, der er tilstrækkelig til at give en PAS-osmolalitet i området fra 290 mOsm til 300 mOsm.
7. Blodpladeadditivopløsning ifølge krav 4 yderligere omfattende 10,0-10,9 mM Na3Citrat, 27,0-32,5 mM Na-acetat og 69,0-115 mM NaCI, og hvor det viskositetsforøgende middel er pentastivelse ved en koncentration i området fra 2 % til 3,5 % vægt/volumen.
8. Blodpladeadditivopløsning ifølge krav 4 yderligere omfattende 10,0-10,9 mM Nascitrat, 27,0-32,5 mM Na-acetat og 69,0-115 mM NaCI, og hvor det viskositetsforøgende middel er polyglycidol ved en koncentration i området fra 3,6 % til 4,6 % vægt/volumen.
9. Blodpladeadditivopløsning ifølge et hvilket som helst af kravene 1 til 8 yderligere omfattende en eller flere af Na-gluconat, NaH2P04, Na2HPC>4, MgCL· og KCI.
10. Opløsningssystem til fremstilling af blodpladekoncentrater omfattende mindst ét viskositetsforøgende middel og blodpladeadditivopløsningskomponenter, hvor det viskositetsforøgende middel og blodpladeadditivopløsningskomponenterne tilvejebringes i mindst én beholder tilvejebragt i effektive koncentrationer til opnåelse af en viskositetsforøgende middel-infunderet blodpladeadditivopløsning med en viskositet, når de kombineres, i området fra 1,128 centipoise til 1,228 centipoise når målt ved 37 °C, og hvor det viskositetsforøgende middel er hydroxyethylstivelse (valgfrit pentastivelse) eller polyglycidol.
11. Opløsningssystem ifølge krav 10, hvor et eller flere af det mindst ene viskositetsforøgende middel og blodpladeadditivopløsningskomponenter tilvejebringes i mindst én steril vandig opløsning.
12. Opløsningssystem ifølge krav 10 eller 11, hvor et eller flere af det mindst ene viskositetsforøgende middel og blodpladeadditivopløsningskomponenter tilvejebringes som et genopløseligt materiale.
13. Opløsningssystem ifølge et hvilket som helst af kravene 10 til 12, hvor den mindst ene beholder er valgt fra en blodpose, en serumflaske, et serumrør og et hætteglas.
14. Opløsningssystem ifølge et hvilket som helst af kravene 10 til 13, hvor blodpladeadditivopløsningskomponenterne omfatter mindst én energikilde, mindst én bufferkomponent, mindst ét chelateringsmiddel, mindst én saltkomponent og valgfrit mindst én metabolisk regulator og/eller membranpolaritetsstabiliserende komponent alle ved effektive koncentrationer.
15. Opløsningssystem ifølge krav 14, hvor den mindst ene saltkomponent tilvejebringes ved en koncentration, der er tilstrækkelig til at give en PAS-osmolalitet i området fra 250 mOsm til 400 mOsm.
16. Opløsningssystem ifølge et hvilket som helst af kravene 10 til 15, hvor blodpladeadditivopløsningskomponenterne omfatter 10,0-10,9 mM Nascitrat, 27,0-32,5 mM Na-acetat og 69,0-115 mM NaCI.
17. Anvendelse af en blodpladeadditivopløsning ifølge et hvilket som helst af kravene 1 til 9 eller et opløsningssystem ifølge krav et hvilket om helst af kravene 10 til 16 til fremstilling af et poolet blodpladekoncentrat.
18. Fremgangsmåde til fremstilling afen buffycoatpool i en blodpladeadditivopløsning omfattende viskositetsforøgende middel, hvor fremgangsmåden omfatter trinnene: a) docking afen koncentreret blodpladeadditivopløsning og en koncentreret opløsning af viskositetsforøgende middel til en eller flere fremstillede buffycoats i blodposer; b) pooling af buffycoats; og c) tilsætning af den koncentrerede blodpladeadditivopløsning og den koncentrerede opløsning af viskositetsforøgende middel til de poolede buffycoats; hvorved blandingen af de poolede buffycoats, den koncentrerede blodpladeadditivopløsning og den koncentrerede opløsning af viskositetsforøgende middel har en viskositet på fra 1,128 centipoise til 1,228 centipoise når målt ved 37 °C, og hvor det viskositetsforøgende middel er hydroxyethylstivelse (valgfrit pentastivelse) eller polyglycidol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83416406P | 2006-07-31 | 2006-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1886559T3 true DK1886559T3 (da) | 2016-04-11 |
Family
ID=38719468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07253015.7T DK1886559T3 (da) | 2006-07-31 | 2007-07-31 | Blodpladeadditivopløsning |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7989159B2 (da) |
| EP (1) | EP1886559B1 (da) |
| AU (1) | AU2007203585B2 (da) |
| CA (1) | CA2595353C (da) |
| DK (1) | DK1886559T3 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8835104B2 (en) * | 2007-12-20 | 2014-09-16 | Fenwal, Inc. | Medium and methods for the storage of platelets |
| JP2014518547A (ja) | 2011-04-07 | 2014-07-31 | フェンウォール、インコーポレイテッド | 削減された残存血漿容積を有する血小板濃縮物を提供するための自動化方法とシステムおよびそのような血小板濃縮物のための貯蔵媒体 |
| US9788539B2 (en) | 2011-05-17 | 2017-10-17 | Velico Medical, Inc. | Platelet protection solution having beta-galactosidase and sialidase inhibitors |
| EP2903430A1 (en) | 2012-10-05 | 2015-08-12 | Velico Medical, Inc. | Platelet additive solution having a beta-galactosidase inhibitor |
| WO2016164693A1 (en) | 2015-04-10 | 2016-10-13 | Board Of Regents, The University Of Texas System | Compositions and methods for prolonged cell storage |
| FR3096265B1 (fr) | 2019-05-20 | 2022-06-03 | Maco Pharma Sa | Composition pour la conservation des plaquettes sanguines |
| US12616192B2 (en) | 2021-07-12 | 2026-05-05 | Washington University | Compositions and methods for preserving or increasing platelet function |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4004975A (en) * | 1975-12-30 | 1977-01-25 | The United States Of America As Represented By The Secretary Of The Navy | Method of isolating and cryopreserving human white cells from whole blood |
| US4473552A (en) * | 1981-03-16 | 1984-09-25 | Jost Leonora I | Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells |
| US4798824A (en) * | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| DE4310974C2 (de) * | 1993-04-03 | 1996-08-01 | Fresenius Ag | Verwendung von Hydroxyethylstärke zur Verbesserung der Mikrozirkulation |
| US5789147A (en) | 1994-12-05 | 1998-08-04 | New York Blood Center, Inc. | Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood |
| US6063624A (en) * | 1997-06-09 | 2000-05-16 | Baxter International Inc. | Platelet suspensions and methods for resuspending platelets |
| US6286119B1 (en) * | 1998-12-22 | 2001-09-04 | Nortel Networks Limited | Delay fault testing with IEEE 1149.1 |
| EP1331941A1 (en) * | 2000-10-13 | 2003-08-06 | Pike Laboratories, Inc. | Organ and biological tissue preservation cold storage solution |
| US20030158507A1 (en) * | 2001-06-26 | 2003-08-21 | Vladimir Serebrennikov | Preservation of blood platelets at cold temperatures |
| US20070031812A1 (en) * | 2003-06-20 | 2007-02-08 | Pall Corporation | Processing of platelet-containing biological fluids |
-
2007
- 2007-07-31 DK DK07253015.7T patent/DK1886559T3/da active
- 2007-07-31 CA CA2595353A patent/CA2595353C/en not_active Expired - Fee Related
- 2007-07-31 US US11/888,003 patent/US7989159B2/en not_active Expired - Fee Related
- 2007-07-31 EP EP07253015.7A patent/EP1886559B1/en not_active Not-in-force
- 2007-07-31 AU AU2007203585A patent/AU2007203585B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20080044803A1 (en) | 2008-02-21 |
| AU2007203585A1 (en) | 2008-02-14 |
| CA2595353A1 (en) | 2008-01-31 |
| CA2595353C (en) | 2013-11-05 |
| AU2007203585B2 (en) | 2013-02-07 |
| EP1886559B1 (en) | 2016-03-23 |
| US7989159B2 (en) | 2011-08-02 |
| EP1886559A2 (en) | 2008-02-13 |
| EP1886559A3 (en) | 2012-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1299110C (en) | Synthetic, plasma-free, transfusible platelet storage medium | |
| AU571616B2 (en) | Medium for storing blood platelets | |
| EP1886559B1 (en) | Platelet additive solution | |
| US20190203176A1 (en) | Platelet Products and Storage Media for Platelet Concentrates | |
| EP2271209B1 (en) | Materials and methods for hypothermic collection of whole blood | |
| US8021830B2 (en) | Method for increasing plasma volume by administering a plasma expander comprising basic alpha keratose | |
| AU2005327576B2 (en) | Compositions and methods for the storage of red blood cells | |
| US20150004694A1 (en) | Medium And Methods For The Storage Of Platelets | |
| WO2020234417A1 (fr) | Composition pour la conservation des plaquettes sanguines | |
| Sputtek | Cryopreservation of red blood cells and platelets | |
| CN105532644A (zh) | 淋巴细胞的冻存方法 | |
| Lionetti et al. | Improved method for the cryopreservation of human red cells in liquid nitrogen with hydroxyethyl starch | |
| Heaton | The quality of red blood cells | |
| JP5568103B2 (ja) | 赤血球の保存のための組成物及び方法 | |
| Wegener et al. | 42-Day Stored RBCs Diluted with Additive Solution Exhibit Decreased Hemolysis | |
| NO874727L (no) | Syntetisk, plasmafritt transfuserbart blodplate-lagringsmedium. | |
| NO164154B (no) | Syntetisk lagringsmedium for blodplater fra mennesker, samt fremgangsmaate for fremstilling av et slikt medium. | |
| HK1152841B (en) | Materials and methods for hypothermic collection of whole blood |